160 C-terminal domain of alpha and beta subunits of F1 ATP synthase
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Nucleosides, nucleotides, and analogues | 79 | 21.8 | 3.62× | q < 0.0001 | |
| Organic oxygen compounds | 5 | 15.7 | 0.32× | q = 2.7e-3 | |
| Benzenoids | 1 | 5.8 | 0.17× | q = 0.05 | |
| Homogeneous non-metal compounds | 2 | 17.0 | 0.12× | q < 0.0001 | |
| Organic acids and derivatives | 1 | 12.2 | 0.08× | q = 1.9e-4 | |
| Homogeneous metal compounds | 2 | 38.7 | 0.05× | q < 0.0001 | |
| Lipids and lipid-like molecules | 0 | 8.8 | 0 | q = 5.7e-4 | |
| Organoheterocyclic compounds | 0 | 12.1 | 0 | q < 0.0001 | |
| Phenylpropanoids and polyketides | 2 | 1.6 | 1.22× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00171 | ATP | ATP | 904 |
| DB16833 | ADP | Adenosine disphosphate | 554 |
| DB02930 | AGS | Adenosine 5'-[gamma-thio]triphosphate | 14 |
| DB07394 | AUR | AUROVERTIN B | 5 |
| DB07347 | AES | 4-(2-Aminoethyl)Benzenesulfonyl Fluoride | 2 |
| DB07384 | — | — | 2 |
| DB08629 | — | — | 2 |
| DB00630 | — | Alendronic acid | 1 |
| DB01077 | — | Etidronic acid | 1 |
| DB05260 | — | — | 1 |
| DB06733 | — | — | 1 |
| DB06734 | — | — | 1 |
| DB11638 | — | — | 1 |
| DB12695 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 1,085 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 556 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 244 |
| AGS | PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER | 9 |
| MGmetal | MAGNESIUM ION | 7 |
| XBC | Cruentaren A | 4 |
| ZH7 | (3~{E},5~{E},7~{E},9~{R},10~{R},11~{E},13~{E},17~{S},18~{S},20~{S})-18-methoxy-20-[(~{R})-[(2~{R},3~{R},4~{S},5~{R},6~{R})-6-[(2~{R})-3-methoxy-2-[(2~{R},4~{S},5~{S},6~{S})-5-[(2~{S},4~{R},5~{R},6~{R})-4-methoxy-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4,6-dimethyl-4-oxidanyl-oxan-2-yl]oxy-propyl]-3,5-dimethyl-2,4-bis(oxidanyl)oxan-2-yl]-oxidanyl-methyl]-10-[(2~{R},3~{S},4~{S},5~{R},6~{S})-5-methoxy-6-methyl-3,4-bis(oxidanyl)oxan-2-yl]oxy-3,5,7,9,13-pentamethyl-17-oxidanyl-1-oxacycloicosa-3,5,7,11,13-pentaen-2-one | 4 |
| ZHD | (3~{E},5~{Z},7~{E},9~{R},10~{S},11~{E},13~{E},15~{E},17~{R},18~{S},20~{S})-20-[(1~{R})-1-[(2~{S},3~{R},4~{R},5~{S},6~{R})-5-[(2~{S},4~{S},5~{S},6~{R})-5-[(2~{S},4~{R},5~{R},6~{R})-4,6-dimethyl-4,5-bis(oxidanyl)oxan-2-yl]oxy-6-methyl-4-oxidanyl-oxan-2-yl]oxy-3-methoxy-6-(3-methoxypropyl)-5-methyl-2,4-bis(oxidanyl)oxan-2-yl]ethyl]-5,18-dimethoxy-3,7,9,11,13,15-hexamethyl-10-[(2~{R},3~{S},4~{R},5~{R},6~{S})-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-17-oxidanyl-1-oxacycloicosa-3,5,7,11,13,15-hexaen-2-one | 4 |
| AUR | AUROVERTIN B | 3 |
| CL | CHLORIDE ION | 2 |
| MRD | (4R)-2-METHYLPENTANE-2,4-DIOL | 2 |
| NAmetal | SODIUM ION | 2 |
| YT3metal | YTTRIUM (III) ION | 2 |
| AES | 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE | 1 |
| DCW | DICYCLOHEXYLUREA | 1 |